Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The team behind the world-leading RECOVERY trial of COVID-19 treatments are leading a new study investigating a potential treatment for people who have been diagnosed with monkeypox. The National Institute for Health and Care Research (NIHR) has commissioned and funded the study. The first patients have now been recruited.

Artist representation of monkeypox virus particles

Monkeypox, a member of the smallpox family of viruses, has historically been rare outside west and central Africa. However, in May this year, an outbreak was identified in the UK, followed by cases appearing in multiple other countries outside Africa. On 23 July this year, the World Health Organization declared monkeypox to be a Public Health Emergency of International Concern. Typical symptoms of monkeypox include a rash with painful blisters, which may be widespread or affect just one part of the body. Other symptoms can include fever, muscle ache, and swelling of lymph glands. Monkeypox usually gets better without treatment but this can take several weeks and, rarely, there may be serious complications.

Although vaccines developed for smallpox may reduce the risk of catching monkeypox, there are currently no proven therapeutics to speed recovery in those who develop the disease. The Placebo-controlled randomised trial of tecovirimat in non-hospitalised monkeypox patients (PLATINUM) study will test the efficacy and safety of tecovirimat, an antiviral treatment originally developed for smallpox.

Tecovirimat (also known as TPOXXÒ) prevents the virus from leaving infected cells, stopping its spread within the body. It was licensed earlier this year by the Medicines and Health products Regulatory Agency (MHRA) for monkeypox based on promising results from initial studies in animals and evidence of safety in healthy human volunteers. It is currently in use for the treatment of patients with severe complications of monkeypox who are admitted to hospital. However, to date there have been no clinical trials to confirm whether the drug can help monkeypox patients recover from the disease.

PLATINUM is being led by Sir Peter Horby, Professor of Emerging Infections and Global Health at the University of Oxford and the Director of the new Pandemic Sciences Institute, and Sir Martin Landray, Professor of Medicine & Epidemiology at Oxford Population Health, the joint chief investigators of the Randomised Evaluation of COVID-19 (RECOVERY) trial. The study also involves experts from the UK Health Security Agency, Chelsea and Westminster Hospital NHS Foundation Trust, and the University of Liverpool, who have experience in the clinical assessment and laboratory analysis of human monkeypox infections in the UK.

Professor Sir Peter Horby said:

‘Monkeypox is a distressing and sometimes dangerous infection. For the benefit of current and future patients worldwide who have been diagnosed with monkeypox, we need definitive evidence that tecovirimat is safe and effective. Although the early data on tecovirimat are promising, only a randomised clinical trial will provide the level of evidence we need to treat patients with confidence. PLATINUM will provide that evidence.’

The full story is available on the University of Oxford website

Visit the Platinum Trial website

Similar stories

Pilot study detects diverse DNA in ingredients of falsified tablets

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.

Expert Comment: Biotechnology allows us to make unprecedented interventions for conservation

In the wake of high-profile reports on the devastating toll human activity has had on global biodiversity, nations are expected to adopt the Convention on Biodiversity post-2020 framework that outlines measures to ensure humans live in harmony with nature.

Researchers call for antimicrobial resistance surveillance to be improved

The number of studies reporting antimicrobial resistance (AMR) data has increased in Africa, South and South East Asia according to new research in the International Journal of Infectious Diseases.

Meta-analysis informed the updated WHO guidelines for treatment of uncomplicated malaria in the first trimester of pregnancy

A new WWARN meta-analysis, commissioned by the World Health Organization and which informed a change to its treatment guidelines, has been published in The Lancet. The study provides compelling evidence that artemether-lumefantrine should now replace quinine as the treatment of choice in the first trimester.

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings

GRAM visualization tool tracks country-level AMR and related metrics

Interactive app allows users to explore data underlying estimates of global AMR burden